# Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer

> **NCT02911350** · PHASE1 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 23 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Hormone Suppressors
- **DRUG:** Paclitaxel
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT02911350
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02911350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02911350, "Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02911350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*